reports
Rockwell Medical Announces Upcoming Poster Presentation at the Nationa...
Rockwell Medical Announces Upcoming Poster Presentation at the National Home Infusion Association’s 2022 Annual Conference WIXOM, Mich., March 09, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced a poster presentation at the , to be held March 12-16 in Nashville, Tennessee. Details of the poster presentation are as follows: Title: Management of Iron Deficienc...
Rockwell Medical, Inc. to Present at Aegis Virtual Conference
Rockwell Medical, Inc. to Present at Aegis Virtual Conference WIXOM, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that the company is scheduled to present at , on Wednesday, February 23rd at 1:30 - 2:00 PM ET. A recording of the presentation will be posted to the after the conference. The presentation will also be available by request to Aegis from Februa...
Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule ...
Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WIXOM, Mich., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Company’s Board of Directors approved an option grant to a new employee to purchase 10,000 shares of the Company’s common stock (the “Inducement Grant”). The Inducement Grant has been gran...
Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate ...
Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea Two product forms of Triferic® are now approved in South Korea WIXOM, Mich., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management worldwide, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received a second regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic® Dialysate (ferric pyrophosph...
Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in So...
Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea -Commercial launch expected in June/July 2022- -Rockwell Medical has an exclusive license agreement with Jeil Pharmaceutical Co., Ltd., for the rights to Triferic® and Triferic® AVNU in South Korea- -More than 82,000 patients receiving hemodialysis annually in So. Korea- WIXOM, Mich., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and i...
Rockwell Medical, Inc. to Present at H.C. Wainwright BioConnect 2022 C...
Rockwell Medical, Inc. to Present at H.C. Wainwright BioConnect 2022 Conference WIXOM, Mich., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced the Rockwell Medical executive management team is scheduled to present at the H.C. Wainwright BioConnect 2022 Conference. The presentation will become publicly available for on-demand listening beginning on Mon...
Rockwell Medical Receives Important Feedback from FDA on its IND Appli...
Rockwell Medical Receives Important Feedback from FDA on its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion WIXOM, Mich., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it received feedback from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application in support of its proposed Phase 2 clinical trial of ...
Rockwell Medical Study Demonstrates No Drug-drug Interaction Between F...
Rockwell Medical Study Demonstrates No Drug-drug Interaction Between Ferric Pyrophosphate Citrate and Unfractionated Heparin Findings confirm results from previous population PK study demonstrating safe and effective anticoagulation along with the delivery of Ferric Pyrophosphate Citrate iron WIXOM, Mich., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced the publication of results in the...
Rockwell Medical, Inc. Provides Third Quarter 2021 Financial and Opera...
Rockwell Medical, Inc. Provides Third Quarter 2021 Financial and Operational Update - Third quarter net sales of $16.0 Million, up 6% sequential quarter-over-quarter and 5% year-over-year - - Company recently submitted Investigational New Drug application with FDA for its proposed clinical trial of FPC as a treatment for iron deficiency anemia in patients receiving home infusion - - Company recently presented Triferic® real world evidence update at ASN Kidney Week 2021; results from pilot observational analysis demonstrate maintenance of hemoglobin and reducti...
Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule ...
Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WIXOM, Mich., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Company’s Board of Directors approved option grants to two new employees to purchase an aggregate of 75,000 shares of the Company’s common stock (the “Inducement Grants”). The Inducement G...
Rockwell Medical Submits Investigational New Drug Application with FDA...
Rockwell Medical Submits Investigational New Drug Application with FDA for its Proposed Clinical Trial of FPC as a Treatment for Iron Deficiency Anemia in Patients Receiving Home Infusion WIXOM, Mich., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in support of its propos...
Rockwell Medical, Inc. to Report Third Quarter 2021 Financial and Oper...
Rockwell Medical, Inc. to Report Third Quarter 2021 Financial and Operating Results on November 15, 2021 WIXOM, Mich., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, November 15 at 4:00 PM ET to discuss its financial results for the three months ended September 30, 2021, and recent operational highlights. To access the conference call, pl...
Rockwell Medical Presents Triferic® Real World Evidence Update at ASN ...
Rockwell Medical Presents Triferic® Real World Evidence Update at ASN Kidney Week 2021 -Results from pilot observational analysis demonstrate maintenance of hemoglobin and reduction of total IV iron requirement in adult patients on Triferic receiving chronic hemodialysis- -Findings align with pivotal trials of Triferic and prior Real World Evidence- WIXOM, Mich., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around t...
Rockwell Medical, Inc. to Present at the H.C. Wainwright 23rd Annual G...
Rockwell Medical, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference WIXOM, Mich., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that members of its executive management team are scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021. The presentation will become publicly available f...
Rockwell Medical, Inc. Announces Inducement Grant Under Nasdaq Listing...
Rockwell Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) WIXOM, Mich., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that a majority of the independent directors serving on the Company’s Board of Directors approved the grant of an option to purchase 350,000 shares of the Company’s common stock to Megan C. Timmins, the C...
Rockwell Medical, Inc. Provides Second Quarter 2021 Financial and Oper...
Rockwell Medical, Inc. Provides Second Quarter 2021 Financial and Operational Update -Entered into exclusive license agreement with Drogsan Pharmaceuticals for the rights to commercialize Triferic® in Turkey- -Extended multi-year distribution agreement with Nipro Medical for dialysis concentrates in LATAM and the Caribbean- -Q2 2021 conference call and webcast scheduled for today at 4:30 p.m. ET- WIXOM, Mich., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment...
Rockwell Medical, Inc. to Report Second Quarter 2021 Financial and Ope...
Rockwell Medical, Inc. to Report Second Quarter 2021 Financial and Operating Results on August 16, 2021 WIXOM, Mich., July 29, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, August 16, 2021, at 4:30 p.m. ET to discuss its financial results for the three months ended June 30, 2021, and recent operational highlights. To access the conference call, ple...
Rockwell Medical, Inc. Files Pre-IND Meeting Request with FDA for its ...
Rockwell Medical, Inc. Files Pre-IND Meeting Request with FDA for its Proposed Clinical Trial of FPC as a Treatment for Iron Deficiency Anemia in Patients Receiving Home Infusion WIXOM, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it has submitted a pre-IND (Investigational New Drug) meeting request with the U.S. Food and Drug Administration (FDA) in support of its proposed...
Rockwell Medical Announces Extension of Multi-Year Distribution Agreem...
Rockwell Medical Announces Extension of Multi-Year Distribution Agreement with Nipro Medical Corporation for Dialysis Concentrates Provides for minimum of approximately $11.4M in purchases over 3-year Period WIXOM, Mich., June 11, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it extended its distribution agreement with its long-term distribution partner, Nipro Medical Corporation (NMC), f...
Rockwell Medical and Drogsan Pharmaceuticals Enter into Exclusive Lice...
Rockwell Medical and Drogsan Pharmaceuticals Enter into Exclusive License Agreement for the Rights to Commercialize Triferic® in Turkey - With approximately 65,000 patients receiving hemodialysis annually, Turkey represents a significant and expanding market opportunity - WIXOM, Mich. and ANKARA, Turkey, June 08, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, and Drogsan Pharmaceuticals, a leading pharmaceutic...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.